Amlenetug
| Clinical data | |
|---|---|
| Other names | Lu AF82422; LuAF82422 |
| Routes of administration | Intravenous infusion |
| Drug class | Monoclonal antibody against α-synuclein |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
| KEGG | |
| ChEMBL | |
Amlenetug (INN, USAN; developmental code name Lu AF82422) is a monoclonal antibody against α-synuclein which is under development for the treatment of multiple system atrophy.[1][2][3] It is or was also under development for the treatment of Parkinson's disease, but no recent development has been reported.[1][2] The drug is given by intravenous infusion.[1] Amlenetug was originated by Genmab and Lundbeck A/S and is being developed by Lundbeck A/S.[1][2] As of March 2025, it is in phase 3 clinical trials for multiple system atrophy.[1][2]
See also
References
- 1 2 3 4 5 "Amlenetug - Lundbeck A/S". AdisInsight. 18 March 2025. Retrieved 27 March 2026.
- 1 2 3 4 "Delving into the Latest Updates on Amlenetug with Synapse". Synapse. 2 March 2026. Retrieved 27 March 2026.
- ↑ Kallunki P, Sotty F, Willén K, Lubas M, David L, Ambjørn M, et al. (May 2025). "Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies". npj Parkinson's Disease. 11 (1) 132. doi:10.1038/s41531-024-00849-1. PMC 12098740. PMID 40404755.